Diagnosis of Tuberculosis in HIV Co-infected Individuals: Current Status, Challenges and Opportunities for the Future

Scandinavian Journal of Immunology

Volumn 86, Issue 2, 2017, Pages 76-82

  Mendez Samperio P ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOARABINOMANNAN;

BACTERIUM CULTURE; DIAGNOSTIC TEST; EXTRAPULMONARY TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MIXED INFECTION; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; REVIEW; SMEAR; TUBERCULOSIS; COINFECTION; COMPLICATION; FORECASTING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRENDS; VIROLOGY;

COINFECTION; FORECASTING; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 85024116042     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12567     Document Type: Review

References (93)

1. World Health Organisation. Global Tuberculosis Report 2016. Geneva, Switzerland: World Health Organisation, 2016. Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf. Accessed 20 December 2016
2. World Health Organisation. Global Tuberculosis Report. Geneva, Switzerland: World Health Organisation, 2015.
3. Hesseling AC, Rabie H. Tuberculosis and HIV remain major causes of death in African children. Int J Tuberc Lung Dis 2016;20:996–7.
4. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in postmortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. Aids 2015;29:1987–2002.
5. Bates M, Mudenda V, Shibemba A et al. Burden of tuberculosis at postmortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. Lancet Infect Dis 2015;15:544–51.
6. Tiberi S, Carvalho AC, Sulis G et al. The cursed duet today: Tuberculosis and HIV-coinfection. Presse Med 2017;46:e23–39.
7. Diagnostic Standards, Classification of Tuberculosis in Adults, Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376–95.
8. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource constrained settings: informing urgent policy changes. Lancet 2007;369:2042–9.
9. Desikan P. Sputum smear microscopy in tuberculosis: is it still relevant? Indian J Med Res 2013;137:442–4.
10. Vittor AY, Garland JM, Gilman RH. Molecular diagnosis of TB in the HIV positive population. Ann Global Health 2014;80:476–85.
11. Ling DI, Flores LL, Riley LW et al. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta- regression. PLoS ONE 2008;3:e1536.
12. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745–55.
13. Steingart KR, Ng V, Henry M et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:664–74.
14. Steingart KR, Henry M, Ng V et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:570–81.
15. World Health Organization. Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis: Policy Statement. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publica-tions/2011/9789241501613_eng.pdf. Accessed 3 August 2016.
16. World Health Organization. The use of Liquid Medium for Culture and DST. Geneva, Switzerland: WHO, 2007. http://www.who.int/tb/laboratory/policy_liquid_medium_for_culture_dst/en/index.html. Accessed 3 August 2016.
17. Gray CM, Katamba A, Narang P et al. Feasibility and operational performance of tuberculosis detection by loop-mediated isothermal amplification platform in decentralized settings: results from a multicenter study. J Clin Microbiol 2016;54:1984–91.
18. World Health Organization. The use of a Commercial Loop-Mediated Isothermal Amplification Assay (TB-LAMP) for the Detection of Tuberculosis. Expert Group Meeting Report. Geneva, Switzerland: WHO, 2013. http://apps.who.int/iris/bitstream/10665/83142/1/WHO_HTM_TB_2013.05_eng.pdf
19. Yuan LY, Li Y, Wang M et al. Rapid and effective diagnosis of pulmonary tuberculosis with novel and sensitive loop-mediated isothermal amplification (LAMP) assay in clinical samples: a meta-analysis. J Infect Chemother 2014;20:86–92.
20. Nliwasa M, MacPherson P, Chisala P et al. The sensitivity and specificity of loop- mediated isothermal amplification (LAMP) assay for tuberculosis diagnosis in adults with chronic cough in Malawi. PLoS ONE 2016;11:e0155101.
21. World Health Organization. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test: Technical and Operational ‘how to’ Practical Considerations. WHO/HTM/TB/2011.2. Geneva, Switzerland: WHO, 2011.
22. Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010;48:229–37.
23. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005–15.
24. ® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampin resistance. Future Microbiol 2011;6:1067–82.
25. World Health Organization. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampin Resistance: Xpert MTB/RIF System for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Policy update. Geneva, Switzerland: WHO, 2013. http://www.stoptb.org/wg/gli/assets/documents/WHO%20Policy%20Statement%20on%20Xpert%20MTB-RIF%202013%20pre%20publication%2022102013.pdf. Accessed 3 August 2016.
26. Detjen AK, DiNardo AR, Leyden J et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med 2015;3:451–61.
27. Friedrich SO, Rachow A, Saathoff E et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013;1:462–70.
28. Theron G, Venter R, Calligaro G et al. Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? Clin Infect Dis 2016;62:995–1001.
29. Puri L, Oghor C, Denkinger CM, Pai M. Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets. Lancet Glob Health 2016;4:e94–5.
30. Scott LE, McCarthy K, Gous N et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011;8:e1001061.
31. Theron G, Peter J, van Zyl-Smit R et al. Evaluation of the Xpert MTB/ RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011;184:132–40.
32. Theron G, Peter J, Meldau R et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013;68:1043–51.
33. ® MTB/RIF assay for pulmonary tuberculosis and rifampin resistance in adults. Cochrane Database Syst Rev 2014;1:CD009593. doi: 10.1002/14651858
34. Cox HS, Mbhele S, Mohess N et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 2014;11:e1001760.
35. Theron G, Zijenah L, Chanda D et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/ RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014;383:424e35.
36. Churchyard GJ, Stevens WS, Mametja LD et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015;3:e450–7.
37. Reed JL, Walker ZJ, Basu D et al. Highly sensitive sequence specific qPCR detection of Mycobacterium tuberculosis complex in respiratory specimens. Tuberculosis 2016;101:114–24.
38. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta- analysis. Eur Respir J 2014;44:435–46.
39. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non- respiratory samples: a systematic review. BMC Infect Dis 2014;14:709.
40. Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger C, Boehme C. Development, roll-out, and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt, and how can we do better? Eur Respir J 2016;48:516–25.
41. Gous N, Scott L, Berrie L et al. Options to expand HIV viral load testing in South Africa: evaluation of the GeneXpert1HIV-1 viral load assay. PLoS ONE 2016;11:e0168244.
42. UNAIDS. 90–90–90 An ambitious treatment target to help end the AIDS epidemic. UNAIDS/JC2684; 2014. Available from: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. [Accessed 2015 February 13].
43. Pathak D, Chakravorty S, Hanif M, Tyagi J. Lysis of tubercle bacilli in fresh and stored sputum specimens: implications for diagnosing tuberculosis in stored and paucibacillary specimens by PCR. BMC Microbiol 2007;7:83.
44. Lawn SD, Kerkhoff AD, Vogt M et al. High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr 2012;60:289–94.
45. Sakamuri RM, Price DN, Lee M et al. Association of lipoarabinomannan with high density lipoprotein in blood: implications for diagnostics. Tuberculosis 2013;93:301–7.
46. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012;12:103.
47. Peter JG, Zijenah LS, Chanda D et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 2016;387:1187–97.
48. World Health Organization. The Use of Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for the Diagnosis and Screening of Active Tuberculosis in People Living With HIV. Policy Update. Geneva, Switzerland: WHO, 2015.
49. Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg 2016;110:180–5.
50. Shah M, Hanrahan C, Wang ZY et al. Lateral flow urine lipoarabinomannan for detecting active tuberculosis in HIV-positive adults. Cochrane Database Syst Rev 2016;5:CD011420.
51. Haas CT, Roe JK, Pollara G et al. Diagnostic ‘omics for active tuberculosis. BMC Med 2016;14:37.
52. WHO. Tuberculosis Diagnostic Technology and Market Landscape, UNITAID. Geneva: WHO, 2015.
53. Furin J, Akugizibwe P, Ditiu L et al. No one with HIV should die from tuberculosis. Lancet 2015;386:e48–50.
54. Alland D, Rowneki M, Smith L et al. Xpert MTB/RIF ultra: a new near-patient TB test with sensitivity equal to culture. Conference on Retroviruses and Opportunistic Infections; 2015 Feb 23–26; Seattle (WA): IAS-USA/CROI Foundation; 2015.
55. Wells WA, Boehme CC, Cobelens FG et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013;13:449–58.
56. Salamon H, Yamaguchi KD, Cirillo DM et al. Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. J Infect Dis 2015;211 (Suppl 2):S50–7.
57. World Health Organisation. The use of Molecular Line Probe Assays for the Detection of Resistance to Isoniazid and Rifampicin. Geneva, Switzerland: World Health Organisation, 2016. Available from: http://apps.who.int/iris/bitstream/10665/250586/1/9789241511261-eng.pdf. Accessed 20 December 2016
58. Bai Y, Wang Y, Shao C et al. GenoType MTBDRplus assay for rapid detection of multidrug resistance in Mycobacterium tuberculosis: a meta-analysis. PLoS ONE 2016;11:e0150321.
59. Nathavitharana RR, Hillemann D, Schumacher SG et al. Multicenter non inferiority evaluation of Hain GenoType MTBDRplus version 2 and Nipro NTMþMDRTB Line Probe Assays for Detection of Rifampin and Isoniazid Resistance. J Clin Microbiol 2016;54:1624–30.
60. Brossier F, Guindo D, Pham A et al. Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug- resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 2016;54:1573–80.
61. World Health Organisation. The use of Molecular Line Probe Assays for the Detection of Resistance to Second-Line Antituberculosis Drugs. Geneva, Switzerland: World Health Organisation, 2016.
62. Chen JH, She KK, Kwong TC et al. Performance of the new automated Abbott RealTime MTB assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimens. Eur J Clin Microbiol Infect Dis 2015;34:1827–32.
63. Kostera J, Leckie G, Tang N et al. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens. Tuberculosis 2016;101:137–43.
64. Hofmann-Thiel S, Molodtsov N, Antonenka U, Hoffmann H. Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF assays for direct detection of Mycobacterium tuberculosis complex and resistance markers in respiratory and extra- pulmonary specimens. J Clin Microbiol 2016;54:3022–7.
65. Schumacher SG, Sohn H, Qin ZZ et al. Impact of molecular diagnostics for tuberculosis on patient-important outcomes: a systematic review of study methodologies. PLoS ONE 2016;11:e0151073.
66. Bates M, Zumla A. The development, evaluation and performance of molecular diagnostics for detection of Mycobacterium tuberculosis. Expert Review Molec Diagn 2016;16:307–22.
67. Witney AA, Cosgrove CA, Arnold A et al. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC Med 2016;14:46.
68. Abubakar I, Lipman M, McHugh TD, Fletcher H. Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment. BMC Med 2016;14:47.
69. Köser CU, Bryant JM, Becq J et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013;369:290–2.
70. Walker TM, Kohl TA, Omar SV et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015;15:1193–202.
71. Galagan JE. Genomic insights into tuberculosis. Nat Rev Genet 2014;15:307–20.
72. Bryant JM, Harris SR, Parkhill J et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 2013;1:786–92.
73. Donoghue HD. Insights into ancient leprosy and tuberculosis using metagenomics. Trends Microbiol 2013;21:448–50.
74. Kay GL, Sergeant MJ, Zhou Z et al. Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe. Nat Commun 2015;6:6717.
75. Sims D, Sudbery I, Ilott NE, Heger A, Ponting CP. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet 2014;15:121–32.
76. Ashton PM, Nair S, Dallman T et al. MinION nanopore sequencing identifies the position and structure of a bacterial antibiotic resistance island. Nat Biotechnol 2015;33:296–300.
77. Gardiner JL, Karp CL. Transformative tools for tackling tuberculosis. J Exp Med 2015;212:1759–69.
78. Layre E, Al-Mubarak R, Belisle JT, Branch Moody D. Mycobacterial lipidomics. Microbiol Spectr 2014;2:1–19.
79. Layre E, Lee HJ, Young DC et al. Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378c. Proc Natl Acad Sci USA 2014;111:2978e83.
80. Young DC, Layre E, Pan S-J et al. In vivo biosynthesis of terpene nucleosides provides unique chemical markers of Mycobacterium tuberculosis infection. Chem Biol 2015;22:516e26.
81. Anderson ST, Kaforou M, Brent AJ et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014;370:1712–23.
82. Zak DE, Penn-Nicholson A, Scriba TJ et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 2016;387:2312–22.
83. Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med 2016;4:213–24.
84. Houben RM, Menzies NA, Sumner T et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Global Health 2016;4:e806–15.
85. Menzies NA, Gomez GB, Bozzani F et al. Aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Global Health 2016;4:e816–26.
86. Pankhurst LJ, Del Ojo EC, Votintseva AA et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 2016;4:49–58.
87. Pai M. Innovations in tuberculosis diagnostics: progress and translational challenges. EBioMedicine 2015;2:182–3.
88. UNITAID. Tuberculosis: diagnostic technology landscape. Semi-annual update. www.unitaid.eu/images/marketdynamics/ publications/TB%20diagnostics%20 update_Dec%202012.pdf
89. Drain PK, Garrett NJ. The arrival of a true point-of-care molecular assay ready for global implementation? Lancet Global Health 2015;3:e663–4.
90. WHO/TDR/FIND. Diagnostics for tuberculosis. Global demand and market potential. www.finddiagnostics.org/export/sites/default/resource-centre/find_ documentation/pdfs/tbdi_full.pdf
91. www.aeras.org/pdf/TB_RD_Business_Case_Draft_3.pdf
92. Lönnroth K, Migliori GB, Abubakar I et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015;45:928–52.
93. Wejse C. Tuberculosis elimination in the post Millennium Development Goals era. Int J Infect Dis 2015;32:152–5.